Abstract:To develop a new interventional oncology technique, "radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus thymidine kinase (GFP/HSV-TK)/ganciclovir (GCV) gene therapy of cholangiocarcinoma." Luciferase/mCherry-labeled cholangiocarcinoma cells and 24 mice with subcutaneously implanted cholangiocarcinoma cells were treated by: (i) a combination of green fluorescent protein (GFP)/HSV-TK/plasmid gene transfection followed by RFH and ganciclovir exposure; (ii) gene therapy alone; (iii) RFH alone; and (iv) phosphate-buffered saline (PBS) to serve as a control (6 mice per group). Cell viabilities were quantified by MTS assay. Bioluminescent optical imaging and transcutaneous ultrasound imaging were used to follow up the tumor growth over 2 weeks. For in-vivo technical validation of the new technique, pigs in two groups received either intrabiliary delivery of GFP/HSV-TK/plasmid using a needle-integrated balloon catheter flowed by RFH enhancement (n = 6) or gene delivery only (n = 6). GFP signal in bile duct walls were quantified by optical imaging.The non- parametric Mann-Whitney U test was used for statistical comparison of variables. MTS assay demonstrated the lowest cell proliferation in combination therapy compared with three control groups (24.0 ± 5.3% vs 41.9 ± 6.4% vs 72.0 ± 9.0% vs 100%, p<0.001). GFP optical imaging confirmed that GFP/HSV-TK gene expression peaked at day 2 after gene transfection. Bioluminescent optical imaging demonstrated the decreased bioluminescence signals in tumors of combination therapy, compared with other control groups (0.71 ± 0.16 vs 1.46 ± 0.21 vs 2.10 ± 0.27 vs 2.36 ± 0.28, p<0.001). Ultrasound imaging showed the smallest tumor volumes of the combination therapy group, compared with other groups (0.90 ± 0.21 VS 1.61 ± 0.21 VS 2.22 ± 0.25 VS 2.50 ± 0.30, p<0.001). optical imaging confirmed higher GFP expression in the bile ducts with RFH enhancement (signal to noise ratio: 1.28 ± 0.61 VS 0.49 ± 0.31, P<0.05). It is feasible to use intratumoral RFH to enhance GFP/HSV-TK/plasmid gene expression and HSV-TK/GCV gene therapy of cholangiocarcinomas.This concept may pave a new avenue for managing pancreatobiliary malignancies.(supported by an NIH RO1EBO12467)

Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer

Cytokine-Induced Killer (cik) Cell Therapy for Patients with Hepatocellular Carcinoma: Efficacy and Safety

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

A method of delivering an anti-p21Ras single-chain antibody fragment to tumor sites in vivo

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Combination Effect of Oncolytic Adenovirus Therapy and Herpes Simplex Virus Thymidine Kinase/ganciclovir in Hepatic Carcinoma Animal Models.

Effects of gamma-interferon gene-modified hepatocytes on murine implanted liver carcinoma

Intrabiliary Radiofrequency Heating-Enhanced Direct Intratumoral GFP/HSV-TK Gene Therapy of Cholangiocarcinoma: A Preclinical Study on Mice and Pigs

Menstrual Blood-Derived Stem Cells As Delivery Vehicles for Oncolytic Adenovirus Virotherapy for Colorectal Cancer

Oncolytic Vaccinia Virus Inhibits Human Hepatocellular Carcinoma Mhcc97-H Cell Proliferation Via Endoplasmic Reticulum Stress, Autophagy and Wnt Pathways

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect

Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells

An Oncolytic Adenovirus Expressing Herpes Simplex Virus-Thymidine Kinase for Targeting Cancer Therapy: an in Vitro Evaluation

Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy

Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering Rna

Oncolytic Adenovirus-Mediated E1A Gene Therapy Induces Tumor-Cell Apoptosis and Reduces Tumor Angiogenesis Leading to Inhibition of Hepatocellular Carcinoma Growth in Animal Model

Enhancing the Anti-Hepatocarcinoma Efficacy of Cytokine Induced Killer Cells by TLS11a-Lipo-hENG scFv/hIP-10 Nanocapsules

[Tumor-selective replication, cytotoxicity and GM-CSF production of oncolytic recombinant adenovirus in KH901 injection]

Oncolytic Adenovirus Programmed by Synthetic Gene Circuit for Cancer Immunotherapy